Objectives: Chimeric antigen receptor T cells (CARTs) against CD19 antigen represent an effective therapy for relapsed/refractory diffuse large B-cell lymphoma (rrDLBCL). There is no diagnostic test able to predict which patients with residual disease will relapse from those that will reach a delayed complete response. Positron emission tomography/computed tomography scan (PET-CT) is characterized by a significant number of false positive results after immunotherapy. Circulating tumor DNA (ctDNA) may be a good-useful tool to quantify minimal residual disease and for monitoring disease response.
Methods: We present a patient with DLBCL treated with CART cells in which we tested the combined use of ctDNA and PET-CT scan.
Results: Disease reassessment with PET-CT scan showed a partial remission (3 weeks) and a very good partial remission (2 months). A clinical progression at 3 months was confirmed with PET-CT scan. Levels of ctDNA progressively decreased and became undetectable. An initial increase in KMT2D p.E4385G variant allele frequency confirmed disease progression.
Conclusions: Our case shows how the complementary use of ctDNA and PET-CT scan could be a helpful tool in the clinical management of these patients.
Keywords: CART therapy; liquid biopsy; relapsed/refractory diffuse large B‐cell lymphoma.
© 2020 The Authors. eJHaem published by British Society for Haematology and John Wiley & Sons Ltd.